AN2 Therapeutics, Inc.
ANTX
$5.65
-$0.33-5.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.17M | 13.30M | 13.34M | 14.11M | 14.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.81M | 37.12M | 38.11M | 37.40M | 39.13M |
| Operating Income | -38.81M | -37.12M | -38.11M | -37.40M | -39.13M |
| Income Before Tax | -36.28M | -34.55M | -35.17M | -33.99M | -37.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.28 | -34.55 | -35.17 | -33.99 | -37.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.28M | -34.55M | -35.17M | -33.99M | -37.38M |
| EBIT | -38.81M | -37.12M | -38.11M | -37.40M | -39.13M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.07 | -1.10 | -1.16 | -1.13 | -1.25 |
| Normalized Basic EPS | -0.67 | -0.69 | -0.73 | -0.71 | -0.73 |
| EPS Diluted | -1.07 | -1.10 | -1.16 | -1.13 | -1.25 |
| Normalized Diluted EPS | -0.67 | -0.69 | -0.73 | -0.71 | -0.73 |
| Average Basic Shares Outstanding | 139.45M | 124.87M | 120.86M | 120.39M | 119.95M |
| Average Diluted Shares Outstanding | 139.45M | 124.87M | 120.86M | 120.39M | 119.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |